Shuo Feng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shuo Feng has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Guoyu Zhou
Department of Geriatric Medicine , Qilu Hospital of Shandong University , Jinan , China , qiluhospital.com
1 shared publication- Jing Han
Department of Acupuncture, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China
1 shared publication - Lin Tian
Acupuncture and Tuina College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, People’s Republic of China
1 shared publication Pengfei Lin
Department of Neurology, Qilu Hospital of Shandong University, Jinan, Shandong, China
1 shared publication- Shengfeng Wang
Department of Epidemiology and Biostatistics, School of Public Health, Peking University
1 shared publication - Tian-Yu Gao
Department of neurology, Qilu Hospital of Shandong University, Jinan, China
1 shared publication
Latest Publications
- 8 March 2026
- Published by SAGE Publications in Journal of Cerebral Blood Flow & Metabolism
- Vol. 46 (6) , 1516-1528
Serum metabolomics coupled with HR-VWI radiomics reveals metabolic alterations in asymptomatic carotid artery stenosis
Asymptomatic carotid artery stenosis (aCAS) increases the risk of ischemic stroke despite lacking clinical symptoms. This study sought to characterize the serum metabolic profile of aCAS and to identify potential biomarkers associated with plaque vulnerability by integrating metabolomics with radiomics. Untargeted metabolomic profiling was performed using liquid chromatography–tandem mass spectrometry (LC–MS/MS) on 72 participants, including 36 aCAS patients and 36 age- and sex-matched healthy controls (HC). Multivariate and univariate statistical analyses were conducted to screen differential metabolites. Candidate biomarkers were prioritized based on variable importance in projection (VIP) scores and random forest (RF) modeling. Plaque vulnerability features were quantified by high-resolution magnetic resonance vessel wall imaging (HR-VWI), and multi-omics analysis assessed associations between metabolites and plaque characteristics. A total of 144 significantly altered metabolites were identified between the aCAS and HC groups. Pathway enrichment analysis indicated that these differential metabolites were predominantly involved in lipid, purine, amino acid, nucleotide, and energy metabolism. Notably, 12R-HETrE, 9S-HOTrE, oleoylcarnitine, crichetocholic acid and 1β,3α,7α-trihydroxy-5β-cholan-24-oic acid—were significantly associated with radiomic markers of plaque vulnerability. This study delineates metabolic alterations in aCAS patients and identifies potential serum metabolic biomarkers associated with plaque vulnerability. Further validation is required.
- 8 March 2026
- Published by SAGE Publications in Journal of Cerebral Blood Flow & Metabolism
- Vol. 46 (6) , 1516-1528
Serum metabolomics coupled with HR-VWI radiomics reveals metabolic alterations in asymptomatic carotid artery stenosis
Asymptomatic carotid artery stenosis (aCAS) increases the risk of ischemic stroke despite lacking clinical symptoms. This study sought to characterize the serum metabolic profile of aCAS and to identify potential biomarkers associated with plaque vulnerability by integrating metabolomics with radiomics. Untargeted metabolomic profiling was performed using liquid chromatography–tandem mass spectrometry (LC–MS/MS) on 72 participants, including 36 aCAS patients and 36 age- and sex-matched healthy controls (HC). Multivariate and univariate statistical analyses were conducted to screen differential metabolites. Candidate biomarkers were prioritized based on variable importance in projection (VIP) scores and random forest (RF) modeling. Plaque vulnerability features were quantified by high-resolution magnetic resonance vessel wall imaging (HR-VWI), and multi-omics analysis assessed associations between metabolites and plaque characteristics. A total of 144 significantly altered metabolites were identified between the aCAS and HC groups. Pathway enrichment analysis indicated that these differential metabolites were predominantly involved in lipid, purine, amino acid, nucleotide, and energy metabolism. Notably, 12R-HETrE, 9S-HOTrE, oleoylcarnitine, crichetocholic acid and 1β,3α,7α-trihydroxy-5β-cholan-24-oic acid—were significantly associated with radiomic markers of plaque vulnerability. This study delineates metabolic alterations in aCAS patients and identifies potential serum metabolic biomarkers associated with plaque vulnerability. Further validation is required.
- Open Access
- 1 January 2026
- Published by Wiley in Pain Research and Management
- Vol. 2026 (1) , 9739777
Lifetime Probability of Developing Migraine: A Novel Epidemiological Perspective Based on Global Burden of Disease Data
Migraine affects over one billion people worldwide and imposes substantial burdens, yet the lifetime risk of developing migraine has been understudied. Using Global Burden of Disease 2021 data, we estimated age‐, sex‐, and location‐specific lifetime probabilities with the adjusted‐for‐multiple‐primaries method, which accounts for competing mortality and life expectancy. Trends were quantified by average annual percentage change, socioeconomic inequality by concentration indices, and future trajectories with autoregressive integrated moving average models. In 2021, the global lifetime probability of migraine was 51.53% (95% CI: 51.51%–51.55%); females faced a higher risk than males (59.84% vs. 41.99%; ratio: 1.42). Regional estimates ranged from 60.58% in Western Europe to 35.63% in Eastern Sub‐Saharan Africa, paralleling the sociodemographic index gradient (high SDI 55.74% vs. low SDI 45.13%). Risk accumulated mainly during early and middle adulthood. The concentration index declined from 0.35 in 1990 to 0.27 in 2021, indicating reduced socioeconomic disparities, while projections suggest global lifetime risk will rise to 57.18% by 2050. Roughly half the world’s population is therefore expected to experience migraine during their lives, with pronounced heterogeneity by sex, region, and socioeconomic level, underscoring the need for targeted public‐health strategies, particularly for younger individuals during high‐riskperiods.
- 1 January 2026
- Published by Wiley in Pain Research and Management
- Vol. 2026 (1) , 9739777
Open AccessLifetime Probability of Developing Migraine: A Novel Epidemiological Perspective Based on Global Burden of Disease Data
Migraine affects over one billion people worldwide and imposes substantial burdens, yet the lifetime risk of developing migraine has been understudied. Using Global Burden of Disease 2021 data, we estimated age‐, sex‐, and location‐specific lifetime probabilities with the adjusted‐for‐multiple‐primaries method, which accounts for competing mortality and life expectancy. Trends were quantified by average annual percentage change, socioeconomic inequality by concentration indices, and future trajectories with autoregressive integrated moving average models. In 2021, the global lifetime probability of migraine was 51.53% (95% CI: 51.51%–51.55%); females faced a higher risk than males (59.84% vs. 41.99%; ratio: 1.42). Regional estimates ranged from 60.58% in Western Europe to 35.63% in Eastern Sub‐Saharan Africa, paralleling the sociodemographic index gradient (high SDI 55.74% vs. low SDI 45.13%). Risk accumulated mainly during early and middle adulthood. The concentration index declined from 0.35 in 1990 to 0.27 in 2021, indicating reduced socioeconomic disparities, while projections suggest global lifetime risk will rise to 57.18% by 2050. Roughly half the world’s population is therefore expected to experience migraine during their lives, with pronounced heterogeneity by sex, region, and socioeconomic level, underscoring the need for targeted public‐health strategies, particularly for younger individuals during high‐riskperiods.